Latest Issue

March 2024 Featured Report: Vaccines
Ensuring Quality

The Postpandemic Future

Precision Nanosystems mRNA-Lipid Nanoparticle Manufacturing Special Report
Special Report

GMP Manufacturing

Archive

Special Reports

Sponsored Content

In order to enhance access to life-saving medicines, the biopharmaceutical industry must prioritize more efficient therapeutic production. However, the environmental impact of manufacturing choices is facing increasing scrutiny. Sustainability opportunities within the biopharmaceutical sector encompass reducing the environmental footprint, addressing resource depletion, and effectively managing waste through repurposing and recycling. During a recent panel discussion, sustainability experts from Sartorius and their collaborators shared valuable insights on enhancing the sustainability of manufacturing processes. These insights encompass adopting single-use technologies, improving process efficiency, and fostering productive collaborations. This Special Report offers extracts from those enlightening discussions, along with relevant excerpts from Sartorius' white paper on sustainability in the biopharmaceutical industry.

Sponsored Content

Antibody–drug conjugates (ADCs) are complex therapeutics that offer a unique combination of selectivity and potency. Commercial demand for ADC therapeutics is projected to continue to increase while facing a very complex development, manufacturing, and supply chains challenges. Given the complexities of ADC development and manufacturing, there are clear advantages to partnering with a single contract development and manufacturing organization (CDMO) that offers a complete set of services. As ADCs continue to grab a larger share of clinical pipelines, it becomes increasingly essential to select a CDMO partner with the experience and expertise to accelerate timelines while minimizing risk. Fill out the form below to read this special report and learn more about ADC market, growth, challenges, and solutions to accelerate ADC pipelines to market.

Ask the Expert Webcasts

Bio-Rad Laboratories
Sponsored Content

This webcast features: Heidi Jones, MBA, Market Development Manager, Chromatography Applications & Collaborations,  Bio-Rad Laboratories.Endotoxins are common pyrogenic impurities in therapeutic protein preparations that make the next steps in the purification process very difficult. They are negatively charged complex aggregates of lipopolysaccharides released in large amounts from the outer membrane of gram-negative bacteria during mechanical cell lysis and death. Their presence in even minute concentrations in therapeutic protein preparations can cause septic shock, tissue injury, and even death.In research samples, endotoxins can hinder accurate data screening and immunological readouts. Endotoxins are extremely thermally stable and insensitive to pH changes, making their removal especially challenging. This webcast will present case studies using various resins that have been successfully used for endotoxin removal. Key Takeaways:

Sponsored Content

This webcast features: William H. Rushton, MS , Process Chromatography Scientist, Bio-Rad Laboratories. Recombinant adeno‐associated viruses (rAAV) are among the most promising vectors for long‐term gene transduction. These viruses have a high degree of safety, making them ideal for gene therapy applications. Significant progress has been made in improving rAAV vector production and purification. In this study, different chromatography workflow solutions were explored to purify rAAV8. Experimental conditions and data will be presented on using anion exchange (AEX) and mixed-mode chromatography to purify rAAV8. Key Takeaways: Thank you for your interest in this webcast. You may submit your request to view the webcast, and you will receive a confirmation email with log-in details.